

# Global C-19 Vaccination Goal and framework for Action

September 2021




**World Health  
Organization**

## ***RECAP* : objective of updated COVID-19 Global Vaccination Strategic Vision**




- ① **Inform country targets and global vaccination goals for 2022** in light of key uncertainties
- ② **Promote equitable approach to vaccination globally**, as part of broader pandemic control strategy
- ③ **Inform global policymaking & access efforts**, investments by financial/donor institutions, R&D groups & manufacturers, and country planning & work

# RECAP: Global C19 Vaccination Strategy included broad consultation



# Process and key timeline for COVID Vaccine Global Vision



# Context and need for coordinated approach to vaccination

## Disease burden



- **250mn+ cases** and nearly **5 million deaths**<sup>1</sup> of COVID-19 declared
- Despite **rapid Vaccine development**, new waves threaten **health systems**, **variants are more transmissible**, & serious **long-term sequelae** reported

## Vaccines as the solution



- Nearly **6 Bn doses** of vaccine already administered
- Global production is now reaching **1.5 billion doses per month**
- In **areas of high coverage**, major reductions in serious disease, hospitalization, death

## Inequities



- However, the **world is not positioned to end the pandemic**
- Access is **highly inequitable**, ranging from 1% to >70%, **depending largely on wealth**


## Challenges



- **Variants continue to emerge**, causing surges of disease & **slowing or reversing** reopening of societies & economies; with **losses potentially >US\$9 trillion** by 2025<sup>2</sup>


1. reported as of September 2021  
2. IMF estimations

# Health and socio-economic goals drive the global COVID-19 vaccination goal



1. as evidence become available

# COVID-19 vaccination coverage targets



- **70% coverage target** driven by health & economic imperatives of rapidly stopping the pandemic; technical analyses on epidemiology & vaccine attributes; and feasibility assessment
- **Interim targets of 10% / 40% coverage** to ensure equitable pace of global vaccine rollout & prioritization of those at highest risk

# Rationale for broad coverage

- **Immunization of all adults with COVID-19 vaccines will provide substantial and important health returns on investment**, is feasible to achieve in all countries with the right investments, is grounded in evidence and is being actively pursued already in many countries;
- **Vaccination of adolescents will further reduce disease burden and provide other important benefits** towards resuming socio-economic activity, as impact on reducing transmission is fully investigated;
- **At-risk investments needed to assure rapid deployment of vaccines** while scientific knowledge advances; building necessary financial infrastructure, supply capacity and delivery services takes time;
- **The global COVID-19 vaccination effort can be leveraged to strengthen primary health-care systems and other immunization activities.**

Note: This broad vaccination scope is underpinned by a thorough technical and feasibility assessment that analyzed: (i) COVID-19 disease and infection epidemiology, (ii) evolving science on COVID-19 vaccines and SARS-CoV-2 virus evolution, (iii) required vaccine doses and global supply, (iv) vaccine and delivery costs, (v) expected health and economic returns on investment, and (vi) political will, financing, supply and programmatic resources.



# The global COVID-19 vaccination goal and targets are anchored in following principles




## Equity

All individuals, populations & countries should have equitable access without financial hardship;




## Quality

Vaccines used should meet international standards through WHO authorization;



## Integrated


Vaccines should be deployed with tests, treatments and public health & social measures;




## Inclusivity

Vaccination must include marginalized, displaced and vulnerable populations.


# Achieving the global COVID-19 vaccination targets requires anticipating and addressing key challenges




Producing an adequate global supply of COVID-19 vaccines



Ensuring sufficient financial and programmatic resources for procurement & delivery



Guaranteeing equitable access to COVID-19 vaccines by all countries, across income groups



Managing risks associated with the emergence of new variants of SARS-CoV-2

# High-level resource requirements




**Worldwide vaccine need:** 11-12 Bn doses

**Worldwide gap:** 5+ Bn doses (*6 Bn doses administered to date*)



**Vaccine production :** 1.5 Bn doses per month



**LIC/LMIC total funding/ financing need :** \$55 Bn, but much of the vaccine requirement has already been contracted

**LICs/LMICs in-country delivery costs :** \$15-\$20 Bn, need to be covered through in-kind, domestic, grants, concessional loans

**New ACT-A Strategy/Budget planned for release by 15 Oct with more detail on the gap that should be covered through COVAX**

# Aligned and coordinated action is needed to achieve the global COVID-19 vaccination targets

## All Countries

Establish national plans and commit to equitable vaccine distribution, including free flow of materials and vaccines; thoroughly report local data through eJRF

## High Coverage Countries

Take urgent actions to get vaccine doses to lower coverage countries through COVAX, AVAT and other means

## CSOs Private Sector

Empower people, communities and partners locally and globally to act in support of demand and equity

## WHO, Gavi, UNICEF, CEPI


Ensure COVAX's success and support end to end impact for equitable, high coverage

## MDBs and Institutions

Ensure sufficient delivering funding and support for procurement

## Manufacturers

Prioritize supply and transparency to ensure global equity and share know-how




Transparency and data as critical enabler, from manufacturers on 'place in the queue', bilateral deals and from countries on accurate and complete data reporting

# Next steps

---



Living document



Public release in the  
near future



Continuously discuss with  
partners & Member States  
and refine as new evidence  
becomes available



**World Health  
Organization**